Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
3
×
clinical trials
life sciences
national blog main
alnylam pharmaceuticals
autoimmune diseases
biotech
biotech ipos
immunotherapy
investing
medicare
national
national top stories
new york blog main
new york top stories
san francisco blog main
san francisco top stories
abeona therapeutics
accelerated approval
accent therapeutics
achilles therapeutics
acute hepatic porphyria
acute myeloid leukemia
akouos
alder biopharmaceuticals
alexion pharmaceuticals
alopecia areata
alx oncology
amarin
amgen
aminolevulinic acid
aridis pharmaceuticals
aristea therapeutics
axitinib
bellus health
berkeley lights
bolt biotherapeutics
boston
boulder/denver blog main
What
market
3
×
new
3
×
drug
advantages
alnylam
arrival
bar
bio
biotech
brings
cleared
companies
data
days
expect
far
gamble
hasn’t
industry
interference
ipo
ipos
life
medco’s
medicine
momentum
mover
nasdaq
ok
patients
payers
pharmaceuticals
physicians
plan
pricing
raised
research
rna
rnai
roundup
Language
unset
Current search:
market
×
new
×
" boston top stories "
×
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug